XTX Topco Ltd Purchases New Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

XTX Topco Ltd bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,329 shares of the company's stock, valued at approximately $366,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC lifted its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Sterling Capital Management LLC lifted its stake in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares during the last quarter. Avanza Fonder AB bought a new stake in BridgeBio Pharma during the fourth quarter worth $181,000. First Bank & Trust bought a new stake in BridgeBio Pharma during the fourth quarter worth $205,000. Finally, Moss Adams Wealth Advisors LLC bought a new stake in BridgeBio Pharma during the fourth quarter worth $208,000. 99.85% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BBIO. HC Wainwright upped their target price on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. Redburn Atlantic began coverage on BridgeBio Pharma in a research note on Monday, March 31st. They issued a "buy" rating and a $50.00 price target for the company. JPMorgan Chase & Co. increased their price target on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday, March 24th. Finally, Scotiabank increased their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $53.00.

Insiders Place Their Bets

In other news, Director Andrea Ellis sold 30,000 shares of the firm's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at $408,600. This trade represents a 71.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares of the company's stock, valued at approximately $769,732,587.50. This represents a 12.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,769,739 shares of company stock worth $329,866,901. Company insiders own 24.66% of the company's stock.

BridgeBio Pharma Stock Down 1.2 %

BridgeBio Pharma stock traded down $0.42 during trading hours on Monday, reaching $35.89. 3,255,228 shares of the company's stock were exchanged, compared to its average volume of 2,281,769. The firm's 50 day simple moving average is $33.91 and its 200 day simple moving average is $30.57. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47. The firm has a market capitalization of $6.81 billion, a PE ratio of -12.59 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. Analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.